Importantly, the field lacks much needed studies that use direct measures of brain inflammation in comorbid patients and appropriate controls, in conjunction with a larger array of serum markers, starting with cytokines targeted by biologics effective for psoriasis (such as IL-17, IL-22, IL-23). This evidence concerns the gene IL22 and psoriasis.